학술논문
Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal riskResearch in context
Document Type
article
Author
Gian Paolo Fadini; Enrico Longato; Mario Luca Morieri; Stefano Del Prato; Angelo Avogaro; Anna Solini; Mariella Baldassarre; Agostino Consoli; Sara Morganet; Antonella Zugaro; Marco Giorgio Baroni; Francesco Andreozzi; Adriano Gatti; Stefano De Riu; Andrea Del Buono; Raffaella Aldigeri; Riccardo Bonadonna; Alessandra Dei Cas; Angela Vazzana; Monica Antonini; Valentina Moretti; Patrizia Li Volsi; Miranda Cesare; Giorgio Zanette; Silvia Carletti; Paola D'Angelo; Gaetano Leto; Frida Leonetti; Luca D'Onofrio; Ernesto Maddaloni; Raffaella Buzzetti; Simona Frontoni; Giselle Cavallo; Susanna Morano; Tiziana Filardi; Umberto Capece; Andrea Giaccari; Antonio C. Bossi; Giancarla Meregalli; Fabrizio Querci; Alessia Gaglio; Veronica Resi; Emanuela Orsi; Stefano Fazion; Ivano G. Franzetti; Cesare Berra; Silvia Manfrini; Gabriella Garrapa; Giulio Lucarelli; Lara Riccialdelli; Elena Tortato; Marco Zavattaro; Gianluca Aimaretti; Franco Cavalot; Guglielmo Beccuti; Fabio Broglio; Bruno Fattor; Giuliana Cazzetta; Olga Lamacchia; Anna Rauseo; Salvatore De Cosmo; Rosella Cau; Mariangela Ghiani; Antonino Di Benedetto; Antonino Di Pino; Salvatore Piro; Francesco Purrello; Lucia Frittitta; Agostino Milluzzo; Giuseppina Russo
Source
The Lancet Regional Health. Europe, Vol 38, Iss , Pp 100847- (2024)
Subject
Language
English
ISSN
2666-7762
Abstract
Summary: Background: Despite the overall improvement in care, people with type 2 diabetes (T2D) experience an excess risk of end-stage kidney disease. We evaluated the long-term effectiveness of dapagliflozin on kidney function and albuminuria in patients with T2D. Methods: We included patients with T2D who initiated dapagliflozin or comparators from 2015 to 2020. Propensity score matching (PSM) was performed to balance the two groups. The primary endpoint was the change in estimated glomerular filtration rate (eGFR) from baseline to the end of observation. Secondary endpoints included changes in albuminuria and loss of kidney function. Findings: We analysed two matched groups of 6197 patients each. The comparator group included DPP-4 inhibitors (40%), GLP-1RA (22.3%), sulphonylureas (16.1%), pioglitazone (8%), metformin (5.8%), or acarbose (4%). Only 6.4% had baseline eGFR 30 mg/g. During a mean follow-up of 2.5 year, eGFR declined significantly less in the dapagliflozin vs comparator group by 1.81 ml/min/1.73 m2 (95% C.I. from 1.13 to 2.48; p